Ireland
--:--IST
Recruiting Not applicable

Effect of ANKASCIN 568-P Products Regulating Blood Lipid

NCT05737355 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2023-04-01
Last updated
2025-08-28

Condition(s) studied

Hyperlipidemias

Investigational drug(s) / intervention(s)

ANKASCIN 568-P Red yeast rice capsulesPlacebo Capsules

ANKASCIN 568-P Red yeast rice capsules: Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.

Placebo Capsules: Maltodextrin was used as a placebo

Study summary

This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or Female women over the age of 20 (women of childbearing age should not be pregnant or breastfeeding during the study period). * A sane and communicative adult. * 18≦BMI≦35. * Sub-healthy people with simple dyslipidemia and those who have been judged by the doctor that they do not need to take hypolipidemic drugs for the time being, or those who insist on not taking drugs. * Screening criteria Low-density lipoprotein cholesterol (LDL-C): 130\~190 mg/dL. screening criteria and high-density lipoprotein cholesterol (HLDL-C): below 50 mg/dL. * Those without other serious diseases (cancer, heart failure, diabetes, myocardial infarction, liver cirrhosis, moderate to severe liver and kidney dysfunction, stroke, etc.). * During the experiment, the daily routine and eating habits should be maintained and not changed deliberately. Exclusion Criteria: * Triglyceride TG≧500 mg/dL. * Blood pressure value: systolic blood pressure ≧ 200 mmHg or diastolic blood pressure ≧ 140 mmHg. * Patients with moderate or severe abnormal liver and kidney function (generally referring to serum aminopyruvate converting enzyme (SGPT), serum glutamate phenylacetate transaminase (SGOT) are more than 3 times the upper limit of normal or have been diagnosed Liver cirrhosis, or glomerular filtration rate eGFR≦30 ml/min/1.73m2). * Pregnant or lactating women. * Those who take traditional Chinese medicine mainly based on red yeast rice. * Those who have undergone surgery within one month. * Those who have serious diseases such as heart, liver, kidney, and hematopoietic system, mentally ill patients who do not meet the inclusion criteria, fail to use the test product according to the regulations so that the efficacy or safety cannot be judged due to incomplete data.

Primary outcome measure(s)

  • Improves total cholesterol (TC) — 24 weeks
    Compare the improvement of total cholesterol (TC) between the test group and the placebo group after taking red yeast rice capsules or placebo capsules for 24 weeks. According to the results of Section 9. Statistical method, whether there is a statistical difference between the two groups.

Trial sites (1)

FacilityCityRegionStatus
Tri-Service General Hospital, National Defense Medical Center, Taipei city, Taipei Taiwan Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05737355 on ClinicalTrials.gov ↗ ← All trials in Taiwan